지노믹트리
Financials
Valuation Metrics
지노믹트리's Market Cap is ₩2451B. At end of 2025 it was ₩6824B. Ranked #716 of 2,405 in KR market (top 30%), #308 of 1,627 on KOSDAQ (top 19%), #77 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 245.11B KRW | KR#716/2,405 Sec#77/231 |
| Revenue | 2.95B KRW | KR#2,358/2,405 Sec#208/231 |
| Net Income | -9.19B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 124.41B KRW | KR#1,627/2,405 Sec#129/231 |
| Net Assets | 121.93B KRW | KR#1,280/2,405 Sec#98/231 |
| Employees | 79 | KR#1,812/2,405 Sec#154/231 |
| Value | ||
| P/B | 2.00x | KR#1,984/2,405 Sec#148/231 |
| P/S | 82.94x | KR#2,376/2,405 Sec#209/231 |
| FCF Yield | -5.27% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -7.54% | KR#1,873/2,405 Sec#137/231 |
| ROA | -7.39% | KR#2,022/2,405 Sec#148/231 |
| Op. Margin | -398.40% | KR#2,342/2,405 Sec#200/231 |
| Revenue Growth | -17.13% | KR#2,077/2,405 Sec#190/231 |
| Financial Health | ||
| Debt Ratio | 2.03% | KR#9/2,405 Sec#4/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | -12.92B KRW | KR#1,772/2,405 Sec#159/231 |
| Cash | 17.47B KRW | KR#1,325/2,405 Sec#103/231 |
| Current Ratio | 60.85x | KR#3/2,405 Sec#1/231 |
| Performance | ||
| 1Y Return | -53.30% | KR#2,091/2,405 Sec#189/231 |
| 1M Return | -19.43% | KR#1,840/2,405 Sec#181/231 |
| From 52W High | -70.48% | KR#2,069/2,405 Sec#172/231 |
| 1Y MDD | -72.03% | KR#2,042/2,405 Sec#176/231 |
| Trading | ||
| Volume | 62,064 shares | KR#841/2,405 Sec#93/231 |
| Trading Value | 606.2M KRW | KR#723/2,405 Sec#76/231 |
| Foreign Own. | 2.71% | KR#1,373/2,405 Sec#127/231 |
| Per Share | ||
| EPS | -370 KRW | KR—/2,405 Sec—/231 |
| BPS | 4,905 KRW | KR#1,518/2,405 Sec#110/231 |
Company Info
Genomictree was established in 2000 as a specialized enterprise for cancer auxiliary diagnosis, listed on KONEX, and then transferred its listing to KOSDAQ in 2019. Headquartered in Yuseong-gu, Daejeon, it possesses DNA methylation biomarker discovery and ultra-sensitive detection technology, developing and commercializing body fluid-based non-invasive early cancer diagnosis products. Its flagship product, EarlyTect-C, received Ministry of Food and Drug Safety approval in 2018 and is sold in domestic hospitals and clinics, with technology transfer completed and product approval applications underway in China.